Study of the Predictive Marker FLT in Patients Suffering From AML

Withdrawn

• Conditions: Acute Myeloid Leukemia

• Registration Number: NCT01599429
• Lead Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Brief Summary

Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.

Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.

The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-31
• Study First Submitted: 2011-11-04
• Study First Submitted QC: 2012-05-14
• Study First Posted: 2012-05-16
• Primary Completion: 2017-10-31
• Study Completion: 2017-12-31
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-09
• Last Update Posted: 2021-04-14

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients 18 years or above at the time of inclusion;
2. Patients newly diagnosed with acute myeloid leukemia;
3. No contraindication or intolerance to any of the components of the standard chemotherapy by induction (7+3);
4. Patients able to give written informed consent.

Exclusion Criteria

1. Patients unable to tolerate decubitus position for at least 45 minutes;
2. Any previous neoplasia or other neoplasia simultaneously;
3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;
4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before the second FLT-TEP was done.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.	September 2015

Trial Locations

Locations (1)

Centre Hospitalier Universitaire de Sherbrooke; 🇨🇦 Sherbrooke, Quebec, Canada